Takeda to List American Depositary Shares on New York Stock Exchange

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the listing and trading of its American Depositary Shares (“ADSs”) on the New York Stock Exchange (“NYSE”) is expected to commence on December 24, 2018. Takeda’s ADSs currently trade over-the-counter. The ADSs will now trade under the ticker symbol “TAK” and The Bank of New York Mellon will continue to act as the depositary bank for the ADS program.

Takeda will maintain its headquarters in Japan and its primary listing on the Tokyo Stock Exchange (the “TSE”), as well as its current listings on local Japanese stock exchanges.

“Our dual listing on the NYSE and TSE reflects our position as a leading global biopharmaceutical company and will provide wider capital markets access with expanded trading hours for our investors worldwide,” said Costa Saroukos, Chief Financial Officer of Takeda. “We look forward to closing our acquisition of Shire in the coming weeks and driving long-term value for our shareholders as a combined company.”

With its listings in Japan and the United States, Takeda will be able to access two of the world’s largest capital markets and is the only pharmaceutical company listed on both the TSE and the NYSE. The new NYSE listing will also facilitate ownership of Takeda shares following its acquisition of Shire plc (“Shire”) (the “Acquisition”) which, subject to the Shire scheme of arrangement being sanctioned by the Jersey court, is expected to complete on January 8, 2019. Under the terms of the Acquisition, Shire shareholders will be entitled to receive $30.33 in cash and either 0.839 new Takeda shares or 1.678 Takeda ADSs for each Shire share held.

In connection with the listing on the NYSE, Takeda filed a registration statement on Form 20-F on December 6, 2018, and Amendment No. 1 thereto on December 17, 2018. Takeda’s Form 20-F is available online at www.sec.gov and will be available online at https://www.takeda.com/investors/reports shortly before the listing. Takeda shareholders have the ability to receive a hard copy of this documentation, free of charge, by contacting Takeda Investor Relations by telephone at +81-3-3278-2306 or by e-mail at takeda.ir.contact@takeda.com.

https://www.businesswire.com/news/home/20181218005892/en/Takeda-Announces-Listing-American-Depositary-Shares-New